Prevention of rheumatic diseases: Strategies, caveats, and future directions

Rheumatic Disease Clinics of North America

Volumn 40, Issue 4, 2014, Pages 771-785

  Finckh, Axel ^a   Deane, Kevin D ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Prediction; Prevention; Rheumatic diseases

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; HYDROXYCHLOROQUINE; METHOTREXATE; RITUXIMAB; ANTIRHEUMATIC AGENT;

ASYMPTOMATIC DISEASE; DISABILITY; DISEASE COURSE; HEALTH CARE COST; HUMAN; INCIDENCE; NONHUMAN; PATHOGENESIS; PATIENT SELECTION; PREMATURE MORTALITY; PRIMARY PREVENTION; PUBLIC HEALTH; REHABILITATION CARE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SECONDARY PREVENTION; SYSTEMIC LUPUS ERYTHEMATOSUS; EARLY DIAGNOSIS; EARLY INTERVENTION; ECONOMICS; PROCEDURES; REHABILITATION; RHEUMATIC DISEASES; RISK REDUCTION; TRENDS;

ANTIRHEUMATIC AGENTS; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; HUMANS; PRIMARY PREVENTION; RHEUMATIC DISEASES; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; TERTIARY PREVENTION;

EID: 84908060597     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.07.010     Document Type: Review

References (84)

1. Wilson J.M., Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968, 65(4):281-393. [in Spanish].
2. Deane K.D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014, 10(4):212-228. 10.1038/nrrheum.2014.6.
3. Public health measures in disease prevention. Science 2012, 337(6101):1468-1470. 10.1126/science.337.6101.1468-b.
4. Ash C., Kiberstis P., Marshall E., et al. Disease prevention. It takes more than an apple a day. Introduction. Science 2012, 337(6101):1466-1467. 10.1126/science.337.6101.1466.
5. Katz D.L., Ali A. Preventive medicine, integrative medicine & the health of the public. Commissioned for the IOM summit on integrative medicine and the health of the public 2009, Institute of Medicine (IOM), Washington, DC.
6. Karlson E.W., Deane K. Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin North Am 2012, 38(2):405-426. 10.1016/j.rdc.2012.04.002.
7. Novotny F., Haeny S., Hudelson P., et al. Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population. Joint Bone Spine 2013, 80(6):673-674. 10.1016/j.jbspin.2013.05.005.
8. Kallberg H., Ding B., Padyukov L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011, 70(3):508-511. 10.1136/ard.2009.120899.
9. Klareskog L., Stolt P., Lundberg K., et al. Anew model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54(1):38-46.
10. Stolt P., Yahya A., Bengtsson C., et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann Rheum Dis 2010, 69(6):1072-1076.
11. Hart J.E., Laden F., Puett R.C., et al. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect 2009, 117(7):1065-1069.
12. Symmons D.P., Bankhead C.R., Harrison B.J., et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997, 40(11):1955-1961.
13. Bengtsson C., Nordmark B., Klareskog L., et al. Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2005, 64(11):1588-1594. 10.1136/ard.2004.031666.
14. Sugar-sweetened soft drink consumption and risk of developing rheumatoid arthritis. American College of Rheumatology 2013 annual meeting 2013, Arthritis Rheum, San Diego (CA). H. Yang, K.H. Costenbader, F. Hu (Eds.).
15. Dietary sodium increases the risk for rheumatoid arthritis among smokers - results from a nested case-control study. American College of Rheumatology 2013 annual meeting 2013, Arthritis Rheum, San Diego (CA). B. Sundström, I. Johansson, S. Rantapää Dahlqvist (Eds.).
16. Maxwell J.R., Gowers I.R., Moore D.J., et al. Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford) 2010, 49(11):2140-2146.
17. Takvorian S., Merola J., Costenbader K. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus 2014, 23(6):537-544. 10.1177/0961203313501400.
18. Patterson R., Germolec D. Review article toxic oil syndrome: review of immune aspects of the disease. JImmunotoxicol 2005, 2(1):51-58. 10.1080/15476910590960143.
19. Perez-Alvarez R., Perez-de-Lis M., Ramos-Casals M., BIOGEAS study group Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013, 25(1):56-64. 10.1097/BOR.0b013e32835b1366.
20. Sudre P., Mathieu F. Kashin-Beck disease: from etiology to prevention or from prevention to etiology?. Int Orthop 2001, 25(3):175-179.
21. van Steensel M.A. Why minocycline can cause systemic lupus - a hypothesis and suggestions for therapeutic interventions based on it. Med Hypotheses 2004, 63(1):31-34. 10.1016/j.mehy.2003.12.040.
22. James J.A., Robertson J.M. Lupus and Epstein-Barr. Curr Opin Rheumatol 2012, 24(4):383-388. 10.1097/BOR.0b013e3283535801.
23. Ebringer A. Rheumatoid arthritis and proteus 2012, Springer-Verlag, London.
24. Scher J.U., Abramson S.B. Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?. Arthritis Res Ther 2013, 15(5):122. 10.1186/ar4360.
25. Scher J.U., Sczesnak A., Longman R.S., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife (Cambridge) 2013, 2:e01202. 10.7554/eLife.01202.
26. Roddy E., Choi H.K. Epidemiology of gout. Rheum Dis Clin North Am 2014, 40(2):155-175. 10.1016/j.rdc.2014.01.001.
27. Arden N.K., Leyland K.M. Osteoarthritis year 2013 in review: clinical. Osteoarthritis Cartilage 2013, 21(10):1409-1413. 10.1016/j.joca.2013.06.021.
28. Sugiyama D., Nishimura K., Tamaki K., et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010, 69(1):70-81. 10.1136/ard.2008.096487.
29. Costenbader K.H., Kim D.J., Peerzada J., et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004, 50(3):849-857. 10.1002/art.20049.
30. Keenan B.T., Chibnik L.B., Cui J., et al. Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis. Arthritis Rheum 2010, 62(11):3196-3210.
31. Lahiri M., Luben R.N., Morgan C., et al. Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European prospective investigation of Cancer-Norfolk and the Norfolk Arthritis Register-the EPIC-2-NOAR Study). Ann Rheum Dis 2013, 73(1):219-226.
32. Karlson E.W., Ding B., Keenan B.T., et al. Association of environmental and genetic factors and gene-environment interactions with risk of developing rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013, 65(7):1147-1156. 10.1002/acr.22005.
33. Sparks J.A., Chen C.Y., Jiang X., et al. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-205009.
34. Hemminki K., Li X., Sundquist J., et al. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum 2009, 60(3):661-668. 10.1002/art.24328.
35. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. NEngl J Med 2003, 349(16):1526-1533.
36. Aho K., Palosuo T., Heliovaara M. Predictive significance of rheumatoid factor. JRheumatol 1995, 22(11):2186-2187.
37. Aho K., von Essen R., Kurki P., et al. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. JRheumatol 1993, 20(8):1278-1281.
38. Del Puente A., Knowler W.C., Pettitt D.J., et al. High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am J Epidemiol 1989, 129(6):1170-1178.
39. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48(10):2741-2749.
40. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(2):380-386.
41. McAdoo S.P., Hall A., Levy J., et al. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis. JClin Rheumatol 2012, 18(7):336-340. 10.1097/RHU.0b013e31826d2005.
42. Olson S.W., Owshalimpur D., Yuan C.M., et al. Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis. Clin J Am Soc Nephrol 2013, 8(8):1312-1318. 10.2215/CJN.10411012.
43. Chen J.H., Pan W.H., Hsu C.C., et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 2013, 65(1):133-140. 10.1002/acr.21824.
44. Laborie L.B., Engesaeter I.O., Lehmann T.G., et al. Screening strategies for hip dysplasia: long-term outcome of a randomized controlled trial. Pediatrics 2013, 132(3):492-501. 10.1542/peds.2013-0911.
45. Chibnik L.B., Keenan B.T., Cui J., et al. Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset. PLoS One 2011, 6(9):e24380.
46. Costenbader K.H., Feskanich D., Mandl L.A., et al. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119(6):503.e1-503.e9. 10.1016/j.amjmed.2005.09.053.
47. Bowman M.A., Leiter E.H., Atkinson M.A. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 1994, 15(3):115-120.
48. Finckh A., Liang M.H., van Herckenrode C.M., et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006, 55(6):864-872. 10.1002/art.22353.
49. Van Dongen H., Van Aken J., Lard L.R., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56(5):1424-1432.
50. van Aken J., Heimans L., Gillet-van Dongen H., et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 2014, 73(2):396-400. 10.1136/annrheumdis-2012-202967.
51. Arend W.P., Firestein G.S. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012, 8(10):573-586. 10.1038/nrrheum.2012.134.
52. Katz S.J., Russell A.S. Palindromic rheumatism: a pre-rheumatoid arthritis state?. JRheumatol 2012, 39(10):1912-1913. 10.3899/jrheum.120995.
53. Abraham R.R. Palindromic rheumatism: strategies to prevent evolution to rheumatoid arthritis. South Med J 2012, 105(6):322. [author reply: 323]. 10.1097/SMJ.0b013e318257c53e.
54. Gonzalez-Lopez L., Gamez-Nava J.I., Jhangri G., et al. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. JRheumatol 2000, 27(1):41-46.
55. James J.A., Kim-Howard X.R., Bruner B.F., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007, 16(6):401-409. 10.1177/0961203307078579.
56. Tada H., Hidaka Y., Izumi Y., et al. Apreventive trial of short-term immunosuppressive therapy in postpartum thyroid dysfunction. Int J Endocrinol Metab 2003, 2:48-54.
57. Tak PP. Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease (PRAIRI). Nederlands Trials Register [Internet]. 2010. Available at: . http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2442.
58. Singh J.A., Reddy S.G., Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011, 23(2):192-202. 10.1097/BOR.0b013e3283438e13.
59. Kim S.C., Newcomb C., Margolis D., et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken) 2013, 65(4):578-584. 10.1002/acr.21817.
60. Deane K.D., O'Donnell C.I., Hueber W., et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010, 62(11):3161-3172.
61. Sokolove J., Bromberg R., Deane K.D., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012, 7(5):e35296. 10.1371/journal.pone.0035296.
62. van de Stadt L.A., Witte B.I., Bos W.H., et al. Aprediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis 2013, 72(12):1920-1926. 10.1136/annrheumdis-2012-202127.
63. Bos W.H., Dijkmans B.A., Boers M., et al. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis 2010, 69(3):571-574. 10.1136/ard.2008.105767.
64. Hjeltnes G., Hollan I., Forre O., et al. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol 2011, 40(6):422-427. 10.3109/03009742.2011.585350.
65. Bartoloni E., Alunno A., Bistoni O., et al. How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmun Rev 2010, 9(10):701-707. 10.1016/j.autrev.2010.06.001.
66. Liang K.P., Gabriel S.E. Autoantibodies: innocent bystander or key player in immunosenescence and atherosclerosis?. JRheumatol 2007, 34(6):1203-1207.
67. Aho K., Salonen J.T., Puska P. Autoantibodies predicting death due to cardiovascular disease. Cardiology 1982, 69(3):125-129.
68. Richette P., Perez-Ruiz F., Doherty M., et al. Improving cardiovascular and renal outcomes in gout: what should we target?. Nat Rev Rheumatol 2014, [Epub ahead of print].
69. Rodrigues T.C., Maahs D.M., Johnson R.J., et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 2010, 33(11):2471-2473.
70. Dubreuil M., Zhu Y., Zhang Y., et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2014, 10.1136/annrheumdis-2014-205269.
71. Harmsen C.G., Stovring H., Jarbol D.E., et al. Medication effectiveness may not be the major reason for accepting cardiovascular preventive medication: a population-based survey. BMC Med Inform Decis Mak 2012, 12:89. 10.1186/1472-6947-12-89.
72. Groopman J., Hartzband P. Your medical mind: how to decide what is right for you 2011, Penguin Books, New York.
73. Hardcastle S.J., Legge E., Laundy C.S., et al. Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int J Behav Med 2014, 10.1007/s12529-014-9402-x.
74. Kucukarslan S.N. Areview of published studies of patients' illness perceptions and medication adherence: lessons learned and future directions. Research in social & administrative pharmacy. Res Social Adm Pharm 2012, 8(5):371-382. 10.1016/j.sapharm.2011.09.002.
75. Hayashi D., Englund M., Roemer F.W., et al. Knee malalignment is associated with an increased risk for incident and enlarging bone marrow lesions in the more loaded compartments: the MOST study. Osteoarthritis Cartilage 2012, 20(11):1227-1233. 10.1016/j.joca.2012.07.020.
76. Factors involved in the decision to take medications to prevent rheumatoid arthritis in first degree relatives of patients with RA. A discrete choice experiment. Annual scientific meeting of the American College of Rheumatology (ACR) 2011, Arthritis & Rheum, Chicago. A. Finckh, M. Liang, M. Escher (Eds.).
77. Anovel screening strategy for preclinical rheumatoid arthritis (RA) in first degree relatives of patients with RA. Annual European Congress of Rheumatology EULAR 2011, Ann Rheum Dis, London. A. Finckh, R. Müller, B. Möller (Eds.).
78. Vilaprinyo E., Forne C., Carles M., Interval Cancer Study Group, et al. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One 2014, 9(2):e86858. 10.1371/journal.pone.0086858.
79. Finckh A., Liang M.H. Anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: bayes clears the haze. Ann Intern Med 2007, 146(11):816-817.
80. Notkins A.L. New predictors of disease. Molecules called predictive autoantibodies appear in the blood years before people show symptoms of various disorders. Tests that detected these molecules could warn of the need to take preventive action. Sci Am 2007, 296:72-79.
81. Wilson J.M.G., Jungner G. Principles and practice of screening for disease 1968, WHO Public Health Papers #34, Geneva.
82. Smerecnik C.M., Mesters I., Verweij E., et al. Asystematic review of the impact of genetic counseling on risk perception accuracy. JGenet Couns 2009, 18(3):217-228. 10.1007/s10897-008-9210-z.
83. Cunningham M.W. Streptococcus and rheumatic fever. Curr Opin Rheumatol 2012, 24(4):408-416. 10.1097/BOR.0b013e32835461d3.
84. Cooper C., Reginster J.Y., Cortet B., et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 2012, 28(3):475-491.